Itochu signs Molcure capital alliance: Itochu stock pre-market at EUR 12.03, minus 1.23 percent
Published on 10/08/2026 at 07:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 7, 2026, Itochu announced a capital alliance agreement with AI drug-discovery company Molcure. Itochu stock was EUR 12.03 pre-market at Lang & Schwarz at 7:45 a.m. CEST on October 8, 2026, down 1.23 percent versus the Lang & Schwarz prior close. The prior close at Lang & Schwarz was EUR 12.18 on October 7, 2026. The announcement was published by MOLCURE.
Pre-market trading
The Lang & Schwarz bid was EUR 11.98 and the ask was EUR 12.08. The price was quoted before the Xetra session, which is scheduled to begin at 9:00 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Itochu stock.
Capital alliance with Molcure
Under the agreement, Molcure will receive an investment from Itochu. The companies aim to combine Molcure’s AI drug-discovery technology with Itochu’s pharmaceutical-development support capabilities and domestic and international business network. The stated objective is to support pharmaceutical and biotechnology companies across the process from creating drug candidates through preclinical and clinical development. Molcure said its technology covers AI-based discovery involving antibodies and peptides. Alliance News reported that Itochu described the planned system as providing consistent support from AI-driven drug discovery through preclinical and clinical development; financial details were not disclosed. Alliance News also identified Itochu as the company signing the agreement.
